It's a mistake to buy these shares before any real announcement about when the new hepatitis-C drugs will come to market.
The best part about Berkshire Hathaway CEO Warren Buffett's annual investor letters is that they always provide some kind of reality check.This year, in one sentence, he takes on one of the biggest diversion tactics of all -- one promulgated by many companies as the way they should be viewed, and then gullibly accepted by investors: EBITDA or earnings before interest, taxes, depreciation and amortization."When Wall Streeters tout EBITDA as a valuation guide, button your wallet," he wrote.Here's the windup to that comment (emphasis added by me):"I won't explain all of the adjustments - some are tiny and arcane - but serious investors should understand the disparate nature of intangible assets: Some truly deplete over time while others in no way lose value. With software, for example, amortization charges are very real expenses. ..."
Silicon valley millionaires are stepping up to become the newest supporters of NORML, the National Organization for the Repeal of Marijuana Laws.
Socionomist Euan Wilson of the Socionomics Institute has demonstrated the views on pot are more restrictive in bull markets and more tolerant in bear markets.
The promised growth from a spinoff of AbbVie has not materialized.
New Jersey legalized medicinal marijuana but the state is much more restrictive than other states like California. So far only 1,700 patients have registered with the state.
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Despite the recent volatility in the company's stock, TG Therapeutics cancer drugs are on track for approval and will ultimately fill a niche where old generic chemotherapies have failed.
Home Depot and Macys were hurt by the spate of severe winter storms in January and a psoriatic athritic drug is a catalyst for buying biopharma Celgene.
An investor short Endocyte explains his negative view on the upcoming European approval decision in ovarian cancer and why the lung cancer study is likely to fail.
The Cannabis Career Institute teaches budding "ganja-preneurs" how to start their own marijuana business, which is still illegal in the state of New York.
GE may currently be underperforming the S&P 500, but that will soon change once it completes its transformation from a financially dominated company back into an industrially focused one.
TheStreet is on top of the quickly-changing marijuana landscape and Jim Cramer tells you what's in the pipeline.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV